Colossal
PrivateLast Round
Series C
Extension
Sep 17, 2025
Est. Valuation
$10.32B
Total Funding Raised
$545M
Company Overview
Colossal Laboratories & Biosciences is a bioscience and genetic engineering company dedicated to developing innovative technologies aimed at advancing genomics, including species de-extinction and ecosystem restoration through the application of CRISPR technology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, ML Platforms
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts, Data as a Service
AI Layer
Application
Keywords
Price History
Caplight MarketPrice™ estimate for Colossal, published with a 90-day delay.
Caplight MarketPrice™
$8.36
per share, as of July 2026
-61.3%
1-year change
The most recent months of MarketPrice™ are available to Caplight clients.
Caplight MarketPrice™ is an estimate of private secondary market pricing, shown here on a delayed basis for illustrative purposes only. It may be incomplete, is subject to change, and may not be relied upon for any purpose or considered investment advice.
Colossal Comparables
Compare Colossal with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Revive & Restore | 71% | |
| Ginkgo Bioworks | 61% | |
| Los Angeles Project | 56% |
For institutional investors. Book with your work email.
Colossal Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Sep 17, 2025 | ||||
| Series C | Jan 15, 2025 | ||||
| Series B | Jan 31, 2023 | ||||
| Grant | Oct 5, 2022 | ||||
| Series A | Mar 9, 2022 | ||||
Seed | Sep 13, 2021 |
For institutional investors. Book with your work email.
Secondary Market Activity
Bids, offers, and trades by month
| Operation | Date | Price | Size | Share Class | Structure |
|---|---|---|---|---|---|
OFFER |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Colossal Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| TWG Global | Series C |
| S32 | Series A |
| Breyer Capital | Series C, Series B, Series A, Seed |
| Global Space Ventures | Seed |
| Untamed Planet | Series A |
| US Innovative Technology Fund | Series B |
| Builders VC | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 30, 2026
Partnered with Endangered Wildlife Trust for bluebuck rewilding.
- Apr 21, 2026
Won a gold Edison Award for mammalian cloning method.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 4, 2026
Colossal attends WIRED World Fair on Nov 4th '26, where its cofounder discusses securing Trump administration support for an initiative to gather DNA samples from endangered species.
- attends_eventOct 23, 2026
Colossal's chief executive attends Peter Diamandis' Moonshots Summit, where he first discusses the Warhound idea with Palmer Luckey.
- launchesOct 14, 2026
Colossal announces an AI platform designed to help accelerate its de-extinction efforts on Oct 14th '26.
- is_developingOct 2, 2026
Colossal is developing a cold-resistant elephant with all of the core biological traits of the woolly mammoth in Texas, with the project now expected to produce a birth in the early 2030s after the estimated genetic edits rise to about 150.
- is_developingSep 27, 2026
Colossal is developing a cold-adapted, mammoth-like elephant by the 2030s by introducing selected genetic traits associated with the extinct species.
For institutional investors. Book with your work email.
Colossal Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Appears On
Curated lists and screens where this company is featured.
Frequently Asked Questions
Common questions about Colossal's valuation, stock price, and market status.
Is Colossal a public or private company?
Colossal is a private company.
What is the current stock price of Colossal?
Colossal is a private company, so its shares have no public market price. Caplight tracks Colossal's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Colossal worth (valuation)?
Colossal's valuation is estimated at $10.3B based on funding round data.
Can I buy Colossal stock?
Colossal shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Colossal's last funding round?
Colossal's most recent funding round was Series C Extension on September 17, 2025.
Who are the main investors in Colossal?
Key investors in Colossal include TWG Global, Breyer Capital, US Innovative Technology Fund, At One Ventures, Tull Investment.
Will Colossal IPO soon?
No public IPO plans have been announced for Colossal.
How can I track Colossal secondary market activity?
Caplight tracks bids, offers, and trades in Colossal's shares on secondary markets.